CoChat

A randomized controlled trial of the efficacy and safety of saxagliptin as add‐on therapy in patients with type 2 diabetes and inadequate glycaemic control on metformin plus a sulphonylurea

Moses, R. G., Kalra, S., Brook, D., Sockler, J., Monyak, J., Visvanathan, J., Montanaro, M., Fisher, S. A. · 2014 · Diabetes, Obesity and Metabolism
Cited by 49

The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.

Abstract

Aims: To evaluate the efficacy and safety of saxagliptin as add‐on therapy in adults with type 2 diabetes with inadequate glycaemic control on metformin plus a sulphonylurea. Methods: In this 24‐week, multicentre, randomized, parallel‐group, double‐blind study, outpatients aged ≥18 years with type 2 diabetes, body mass index ≤40 kg/m 2 and inadequate glycaemic control, received saxagliptin 5 mg or placebo once‐daily added to background medication consisting of a stable maximum tolerated dose of metformin plus a sulphonylurea. The primary end point was change in glycated haemoglobin (HbA1c) from baseline to week 24. Safety and tolerability assessments included adverse events (AEs), hypoglycaemia and body weight. Results: A total of 257 patients were randomized, treated and included in the safety analysis (saxagliptin, n = 129; placebo, n = 128); 255 were included in the efficacy analysis (saxagliptin, n = 127; placebo, n = 128). HbA1c reduction was greater with saxagliptin versus placebo [between‐group difference in adjusted mean change from baseline, −0.66%; 95% confidence interval (CI), −0.86 to −0.47 (7 mmol/mol, −9.4 to −5.1); p < 0.0001]. The proportion of patients with ≥1 AE was 62.8% with saxagliptin and 71.7% with placebo. In the saxagliptin and placebo groups, rates of reported hypoglycaemia were 10.1 and 6.3%, respectively, and rates of confirmed hypoglycaemia (symptoms + glucose < 2.8 mmol/l) were 1.6 and 0%. Mean change in body weight was 0.2 kg for saxagliptin and −0.6 kg for placebo (p = 0.0272). Conclusion: Addition of saxagliptin 5 mg/day in patients inadequately controlled on metformin and sulphonylurea effectively improved glycaemic control and was well tolerated.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/dom.12234

Cites

7 of 7 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 7 references

Cited by

See all 49

Metadata

Authors
Moses, R. G., Kalra, S., Brook, D., Sockler, J., Monyak, J., Visvanathan, J., Montanaro, M., & Fisher, S. A.
Venue
Diabetes, Obesity and Metabolism
Publisher
Wiley
Published
2013-12-08
Volume
16
Issue
5
Pages
443-450
ISSN
  • 1462-8902 (ISSN-L)
  • 1463-1326
OpenAlex
W2025791731
Cited by
49
References
7
FWCI
7.55
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: A randomized controlled trial of the efficacy and safety of saxagliptin as add‐on therapy in patients with type 2 diabetes and inadequate glycaemic control on metformin plus a sulphonylurea. https://app.cochat.ai/papers/10.1111/dom.12234
The paper
Moses, R. G., Kalra, S., Brook, D., Sockler, J., Monyak, J., Visvanathan, J., Montanaro, M., & Fisher, S. A. (2014). A randomized controlled trial of the efficacy and safety of saxagliptin as add‐on therapy in patients with type 2 diabetes and inadequate glycaemic control on metformin plus a sulphonylurea. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/dom.12234

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.